Focus on Baseline LDL-C and Patient Risk, Not Drug Type: A Perspective on Alirocumab vs Evolocumab
Reviews in Cardiovascular Medicine · 21.04.2026 · 27 (4)
DOI: 10.31083/rcm50430 ↗Kurz gefasst
Editorial in der Zeitschrift Reviews in Cardiovascular Medicine, online erschienen am 21.04.2026. Verfasst von Pierre Sabouret und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Sorbonne University, 75013 Paris, France. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Cardiology, Sorbonne University, 75013 Paris, France.
- Department of Systems Medicine, "Tor Vergata" University, 00133 Rome, Italy.
- Department of Cardiology, Royal Stoke University Hospital, University Hospitals of North Midlands NHS Trust, ST4 6QG Stoke-on-Trent, UK.
- Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University, ST5 5BG Keele, UK.
ORCID-Profile: Pierre Sabouret, Domenico Mario Giamundo, Mamas Mamas
Zitieren
APA
Sabouret, P., Giamundo, D. M., & Mamas, M. (2026). Focus on Baseline LDL-C and Patient Risk, Not Drug Type: A Perspective on Alirocumab vs Evolocumab. Reviews in Cardiovascular Medicine, 27(4). https://doi.org/10.31083/rcm50430
Vancouver
Sabouret P, Giamundo DM, Mamas M. Focus on Baseline LDL-C and Patient Risk, Not Drug Type: A Perspective on Alirocumab vs Evolocumab. Reviews in Cardiovascular Medicine. 2026;27(4). doi:10.31083/rcm50430
BibTeX
@article{Sabouret2026,
author = {Sabouret, Pierre and Giamundo, Domenico Mario and Mamas, Mamas},
title = {Focus on Baseline LDL-C and Patient Risk, Not Drug Type: A Perspective on Alirocumab vs Evolocumab},
journal = {Reviews in Cardiovascular Medicine},
year = {2026},
volume = {27},
number = {4},
doi = {10.31083/rcm50430}
}
EUVIMED